Newton Newswire

Comprehensive Real-Time News Feed for Newton, MA.

Results 1 - 15 of 15 for "u:biospace.com" in Newton, MA

  1. Karyopharm To Present At The Jefferies 2016 Healthcare ConferenceRead the original story

    Tuesday May 31 | BioSpace

    Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Chief Financial Officer of Karyopharm, is scheduled to present at the upcoming Jefferies 2016 Healthcare Conference in New York City on Wednesday, June 8, 2016 at 3:00 p.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at .

    Comment?

  2. ProteoThera, Inc. Receives Allowance For A Broad U.S. Patent Covering Matrix-Binding TechnologyRead the original story

    May 8, 2016 | BioSpace

    ProteoThera, Inc., a biotechnology company with a platform technology for local, targeted drug delivery, announced today that a notice of allowance has been received from the U.S. Patent and Trademark Office for a patent entitled "Targeted Therapeutics," to which ProteoThera has exclusive worldwide rights through its existing agreement with Brigham and Women's Hospital. The allowed patent describes composition-of-matter claims covering fusions of the ProteoThera matrix-binding sequences with any active therapeutic agent.

    Comment?

  3. Nanotherapeutics Closes Sale-Leaseback Financing With Senior Housing...Read the original story

    May 5, 2016 | BioSpace

    Nanotherapeutics, an integrated biopharmaceutical company with a focus on advanced development and manufacturing, today announced the closing of a sale-leaseback transaction with Senior Housing Properties Trust, or SNH, for the company's new Advanced Development and Manufacturing Facility in Alachua, FL. The transaction, under which Nanotherapeutics sold the property for $45 million and entered into a 15-year lease, provides the company with long term financing for the 183,000 square foot, state-of-the-art, multi-purpose-multi-product, Biosafety Level-3 capable facility.

    Comment?

  4. Karyopharm To Report First Quarter 2016 Financial Results On May 9, 2016Read the original story

    May 1, 2016 | BioSpace

    Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, announced today that it will report first quarter 2016 financial results and provide a company update on Monday, May 9, 2016. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, May 9, 2016 to discuss the financial results and recent business developments.

    Comment?

  5. Karyopharm Presents Data Demonstrating The Potential Of Nuclear...Read the original story

    Apr 19, 2016 | BioSpace

    Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, today announced preclinical data demonstrating the activity of its Selective Inhibitor of Nuclear Export compound, KPT-350, in rodent models of traumatic brain injury . These data were presented at the 2016 Annual Meeting of the American Academy of Neurology taking place April 15-21 in Vancouver, Canada.

    Comment?

  6. Karyopharm Receives National Institute of Allergy And Infectious...Read the original story

    Mar 30, 2016 | BioSpace

    Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, today announced that it has been awarded a grant from the National Institute of Allergy and Infectious Disease to advance development of KPT-350, an oral Selective Inhibitor of Nuclear Export / SINEa compound for the treatment of inflammatory, autoimmune and neurological diseases. The $225,000 grant will be used to conduct further preclinical studies of KPT-350 for the treatment of systemic lupus erythematosus, or lupus, a chronic, autoimmune disease that causes the body to create autoantibodies that attack and destroy healthy tissue, causing inflammation, pain, and damage in various parts of the body.

    Comment?

  7. Karyopharm Reports Fourth Quarter And Full Year 2015 Financial...Read the original story

    Mar 13, 2016 | BioSpace

    NEWTON, Mass., March 14, 2016 -- Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, today reported financial results for the fourth quarter and full year 2015 and commented on recent accomplishments and clinical development plans for its pipeline of several SINE-based therapeutics including selinexor, its lead product candidate. "During 2015, we continued to expand our leadership position in the development of oral SINE-based oncology and non-oncology therapies with clinical advancement of selinexor across a number of hematologic and solid tumor indications and the presentation of encouraging data on our earlier-stage pipeline programs," said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm.

    Comment?

  8. Karyopharm To Present At The 5th Annual Global Healthcare ConferenceRead the original story

    Feb 2, 2016 | BioSpace

    Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming Leerink Partners 5th Annual Global Healthcare Conference in New York on Wednesday, February 10, 2016 at 11:30 a.m. ET. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at .

    Comment?

  9. Karyopharm Initiates Second Generation SINE Compound Clinical Trial in Multiple MyelomaRead the original story

    Jan 18, 2016 | BioSpace

    Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, announced today the initiation of a Phase 1/2 study of oral KPT-8602, a novel, second generation, small-molecule selective inhibitor of nuclear export protein XPO1, in patients with relapsed/refractory multiple myeloma . This first-in-human study is designed to evaluate the safety, tolerability and activity of approximately eight dose levels of KPT-8602 in up to 116 patients in multiple centers in the United States and Canada.

    Comment?

  10. Karyopharm Initiates Clinical Trial Of Oral Selinexor In Advanced LiposarcomaRead the original story

    Jan 13, 2016 | BioSpace

    NEWTON, Mass., Jan. 14, 2016 -- Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, announced today the initiation of iposarcoma , a new Phase 2/3 clinical trial with oral selinexor, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export compound that inhibits exportin 1 . SEAL is a multi-center, randomized, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating single-agent oral selinexor in patients with advanced unresectable dedifferentiated liposarcoma.

    Comment?

  11. Karyopharm To Present At The 34th Annual J.P. Morgan Healthcare ConferenceRead the original story

    Jan 3, 2016 | BioSpace

    Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming J.P. Morgan 34th Annual Healthcare Conference in San Francisco on Wednesday, January 13, 2016 at 8:30 a.m. PT. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at .

    Comment?

  12. Massachusetts-Based Startup Banks $53 MillionRead the original story

    Dec 8, 2015 | BioSpace

    Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on developing and commercializing innovative non-systemic oral protein therapeutics to treat metabolic and orphan diseases, today announced the successful completion of a $53 million Series C financing. Allena intends to use the proceeds from the financing to advance its lead product candidate, ALLN-177 for the treatment of secondary hyperoxaluria in patients with a history of calcium oxalate kidney stones, into Phase 3 clinical trials.

    Comment?

  13. Karyopharm To Present Clinical Data Update For Selinexor (KPT-330) In Hematologic MalignanciesRead the original story

    Nov 30, 2015 | BioSpace

    Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, today announced the presentation of clinical data for its lead drug candidate, selinexor , a first-in-class, oral Selective Inhibitor of Nuclear Export / SINEa compound, during a Karyopharm-sponsored event with webcast scheduled for Monday, December 7, 2015 from 8:30 - 9:30 p.m. ET, immediately following formal programming for the 57th American Society of Hematology Annual Meeting.

    Comment?

  14. Chiasma To Present At Upcoming Investor ConferencesRead the original story

    Nov 10, 2015 | BioSpace

    NEWTON, Mass., Nov. 11, 2015 -- Chiasma, Inc. , a late-stage biopharmaceutical company developing Mycapssaa , an investigational oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today announced that management will provide an overview of the company during two upcoming investor conference presentations: Oppenheimer & Co. 26th Annual Healthcare Conference in New York City on Tuesday, December 8, 2015 at 8:00 a.m. ET.

    Comment?

  15. Karyopharm Initiates STOMP Clinical Trial Of Oral Selinexor In Multiple MyelomaRead the original story

    Oct 18, 2015 | BioSpace

    NEWTON, Mass., Oct. 19, 2015 -- Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company, announced today the initiation of the atients, study. STOMP is a multi-center, Phase 1b/2 study of selinexor and other standard therapies in patients with multiple myeloma .

    Comment?

Newton Job Listings
View or post Newton job listings on Topix.
Newton Real Estate
News, listings, and foreclosures in Newton from Topix.
Newton Mortgages
Find mortgage rates in Newton on Topix.